What options are there to do a genetical analysis of my tumor?What are the potential benefits, risk and trade offs....

I'll help break down the genetic testing options for anal squamous cell carcinoma (SCCA), specifically addressing your HPV-negative status and treatment context.

According to NCCN Guidelines for Anal Carcinoma (2023):

OVERVIEW:

1. Pre-treatment Testing:

• Molecular testing is recommended particularly for HPV-negative cases as they often have different molecular profiles
• Key biomarkers include: PD-L1, MSI/MMR status, and tumor mutational burden (TMB)

1. Post-treatment Testing:

• Additional molecular profiling may be valuable if there's disease progression after standard therapy
• Can help identify potential targeted therapy options or clinical trial eligibility

RECOMMENDED TESTING (per ASCO Guidelines):

1. Essential Tests:

• MSI/MMR status
• PD-L1 expression
• Comprehensive genomic profiling

Main Testing Companies & Coverage:

1. Foundation Medicine Pros:

• FDA-approved comprehensive testing
• Widely accepted by insurance including Cigna
• Extensive panel covering 324+ genes Cons:
• Longer turnaround time (2-3 weeks)
• May require prior authorization

1. Caris Life Sciences Pros:

• Comprehensive molecular profiling
• Good insurance coverage
• Includes RNA sequencing Cons:
• More expensive if not covered
• Variable turnaround times

1. Tempus Pros:

• Fast turnaround time
• AI-powered analysis
• Good for rare cancers Cons:
• More limited insurance coverage
• Newer to market

According to the National Cancer Institute's recommendations:

TIMING CONSIDERATIONS: Pre-treatment:

• Helps guide initial therapy decisions
• May identify clinical trial opportunities
• More tissue typically available

Post-treatment:

• Can guide second-line therapy
• May identify resistance mechanisms
• Limited by tissue availability

Summary Table:

Test Type | Pre-treatment | Post-treatment ---|---|--- MSI/MMR | Essential | Recommended PD-L1 | Essential | Recommended Comprehensive Genomic Profiling | Recommended | Essential Targeted Panel | Optional | Recommended

RECOMMENDATIONS:

1. For your specific case (HPV-negative SCCA):

• Comprehensive molecular profiling is strongly recommended due to HPV-negative status
• Foundation Medicine's FDA-approved test would be the primary recommendation due to:
  • Cigna coverage
  • Comprehensive analysis
  • Established track record

1. Testing Timeline:

• If pre-treatment: Proceed before starting therapy if possible
• If post-treatment: Consider testing if:
  • Disease progression occurs
  • Clinical trial options are being considered

Always discuss with your oncology team as they can:

• Coordinate testing
• Handle insurance authorization
• Interpret results in context of your specific case

Sources:

1. NCCN Guidelines for Anal Carcinoma (2023)
2. ASCO Molecular Testing Guidelines (2022)
3. National Cancer Institute Biomarker Testing Guidelines

Remember: This information is meant to inform discussions with your healthcare team, who can provide personalized recommendations based on your specific clinical situation.